Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223242 · ClinicalTrials.gov registry record · Phase 2

Tailored Exercise Training Study Among Adults With HFpEF

A Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Diabetic Cardiomyopathies, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
1
Study location

NCT07223242: Recruiting Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Diabetic Cardiomyopathies, sponsored by University of Texas Southwestern Medical Center.

NCT07223242 is a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Diabetic Cardiomyopathies that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 120 participants, below the 9,861-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223242, a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Diabetic Cardiomyopathies, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers. This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare four different lifestyle interventions for their effects on exercise capacity.

Primary Outcome

VO2peak indexed to body weight (mL/kg/min) will be the co-primary outcome for the trial. VO2peak is a gold-standard measure of aerobic exercise capacity and will be measured by maximal exercise test using a previously established ergometer protocol

Interventions

  • BEHAVIORAL Resistance training
  • BEHAVIORAL Moderate-intensity continuous training (MCT)
  • DRUG Weight loss

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-02-18
Est. Completion 2026-12-30
Phase Phase 2

What NCT07223242 shows while recruiting

NCT07223242 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 9,861-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with HFpEF - Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 3 interventions - of which Resistance training is the first listed.

NCT07223242 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07223242 about?

NCT07223242 is a clinical study titled "Tailored Exercise Training Study Among Adults With HFpEF". Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI lead...

What is the current status of trial NCT07223242?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-02-18. Estimated completion is 2026-12-30.

What conditions does trial NCT07223242 study?

This clinical trial studies the following conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies.

What interventions are being tested in trial NCT07223242?

The interventions under investigation include: Resistance training (BEHAVIORAL), Moderate-intensity continuous training (MCT) (BEHAVIORAL), Weight loss (DRUG).

Who is sponsoring clinical trial NCT07223242?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223242 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HFpEF - Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07223242, the US trial registry maintained by the National Library of Medicine. NCT07223242 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.